Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer
Public ClinicalTrials.gov record NCT00002889. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
PROGNOSTIC SIGNIFICANCE OF ENDORECTAL MRI IN PREDICTING OUTCOME AFTER COMBINED RADIATION AND ANDROGEN SUPPRESSION FOR PROSTATE CANCER: A PROSPECTIVE PHASE II STUDY
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Imaging procedures such as MRI may improve the ability to determine the response of prostate tumors to therapy. PURPOSE: Phase II trial to study MRI results in patients with prostate cancer that has been treated with radiation therapy plus androgen suppression therapy.
Study identification
- NCT ID
- NCT00002889
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 180 participants
Conditions and interventions
Conditions
Interventions
- flutamide Drug
- goserelin Drug
- leuprolide acetate Drug
- low-LET photon therapy Radiation
Drug · Radiation
Eligibility (public fields only)
- Age range
- 30 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 1997 (Type not available)
- Primary completion
- Jan 2004 (Actual)
- Completion
- Jun 2009 (Actual)
- Last update posted
- Aug 18, 2023
1997 – 2009
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCSF Cancer Center and Cancer Research Institute | San Francisco | California | 94115-0128 | — |
| Walter Reed Army Medical Center | Washington D.C. | District of Columbia | 20307-5000 | — |
| University of Chicago Cancer Research Center | Chicago | Illinois | 60637 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Joint Center for Radiation Therapy | Boston | Massachusetts | 02215 | — |
| St. Joseph's Hospital and Medical Center | Paterson | New Jersey | 07503 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263-0001 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10021 | — |
| Duke Comprehensive Cancer Center | Durham | North Carolina | 27710 | — |
| Comprehensive Cancer Center of Wake Forest University Baptist Medical Center | Winston-Salem | North Carolina | 27157-1082 | — |
| Arthur G. James Cancer Hospital - Ohio State University | Columbus | Ohio | 43210 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425-0721 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00002889, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 18, 2023 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00002889 live on ClinicalTrials.gov.